Ignite Creation Date:
2024-05-06 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 2:24 PM
Study NCT ID:
NCT05233176
Status:
RECRUITING
Last Update Posted:
2023-03-16
First Post:
2022-01-28
Brief Title:
Kinetics of C-Reactive Protein During the Management of Acute Coronary Syndrome Treated by Transluminal Angioplasty
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Kinetics of C-Reactive Protein During the Overall Management of Acute Coronary Syndrome Treated by Transluminal Angioplasty
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CRP KIN
Brief Summary:
The primary objective of the study focuses on the kinetics of plasma CRP measured during the overall management before the angioplasty procedure until the discharge of hospitalization of patients with ST ACS requiring emergency transluminal angioplasty
Detailed Description:
During the management of acute coronary syndrome with ST segment elevation ACS-ST an ischemia-reperfusion syndrome is observed in connection with primary coronary occlusion ischemia and percutaneous angioplasty during the therapeutic coronary reperfusion
This ischemia-reperfusion syndrome results biologically in an inflammatory syndrome evaluated in particular by the assay of C-reactive protein CRP CRP is a marker of inflammation used in routine practice Previous studies have reported the prognostic value of CRP at the 48th hour of hospital treatment for ST ACS If the value of CRP is correlated with the risk of mortality and heart failure the fact remains that no study has to date studied its kinetics during the overall management pre and intra-hospital of ACS ST This is all the more important since the previous therapies taken by the patient statins for example andor those administered during treatment colchicine ticagrelor anti-GPIIbIIIa are capable of modifying the pre-hospital value of the CRP
In this study the kinetics of plasma CRP measured during the first medical contact emergency cardiology or resuscitation then in the catheterization room before the angioplasty procedure then in the catheterization room after the angioplasty then at the 6th hour H6 at the 12th hour H12 at the 24th hour H24 at the 48th hour H48 and once a week until the 7th day then once a week until discharge hospitalization with a maximum of 30 days of follow-up as part of the usual follow-up of patients with ST ACS requiring emergency transluminal angioplasty
This ischemia-reperfusion syndrome results biologically in an inflammatory syndrome evaluated in particular by the assay of C-reactive protein CRP CRP is a marker of inflammation used in routine practice Previous studies have reported the prognostic value of CRP at the 48th hour of hospital treatment for ST ACS If the value of CRP is correlated with the risk of mortality and heart failure the fact remains that no study has to date studied its kinetics during the overall management pre and intra-hospital of ACS ST This is all the more important since the previous therapies taken by the patient statins for example andor those administered during treatment colchicine ticagrelor anti-GPIIbIIIa are capable of modifying the pre-hospital value of the CRP
In this study the kinetics of plasma CRP measured during the first medical contact emergency cardiology or resuscitation then in the catheterization room before the angioplasty procedure then in the catheterization room after the angioplasty then at the 6th hour H6 at the 12th hour H12 at the 24th hour H24 at the 48th hour H48 and once a week until the 7th day then once a week until discharge hospitalization with a maximum of 30 days of follow-up as part of the usual follow-up of patients with ST ACS requiring emergency transluminal angioplasty
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2021-A02081-40 | OTHER | IDRCB | None |